

H.R. 6130/S. 3267

# PASS THE ASAP ACT

## ALZHEIMER'S SCREENING & PREVENTION ACT

More than 7 million Americans have Alzheimer's disease—which until recently, could only be diagnosed with an expensive scan or invasive procedure. In 2025, the U.S. Food and Drug Administration cleared two biomarker tests for Alzheimer's disease. These biomarker tests are Blood Based Biomarkers (BBBs) that look for specific proteins and other markers in a routine blood sample. These BBB tests are an important step forward in Alzheimer's care. Unfortunately, federal law currently prevents Medicare from covering these tests except in very limited circumstances.



## THE BIPARTISAN, BICAMERAL ASAP ACT ENSURES:



### EASIER ACCESS

Ensures that older adults would have timely access to innovative diagnostic tests that can detect Alzheimer's disease and related dementias.



### LESS INVASIVE

BBB tests provide patients with a much less invasive screening option than traditional PET scans and spinal taps.



### EARLIER DETECTION

This technology offers earlier detection of Alzheimer's allowing more time to begin FDA-approved therapies proven to slow the disease's progression.

We thank Representatives Vern Buchanan (R-FL) and Paul Tonko (D-NY), and Senators Susan Collins (R-ME), Catherine Cortez Masto (D-NV) and Mark Warner (D-VA) for introducing the ASAP Act.

Learn more at [AgingResearch.org](https://AgingResearch.org)

